Actually, in a study about the role of tumor-infiltrating B cells and intratumorally-produced antibodies in cancer-immunity interactions, Isaeva et al. (2019) found that plasma cells produced a great number of clonal IgG1, which was not much effective on prognosis, suggesting that IgG1+ tumor-infiltrating B cells might exert a beneficial effect in KRAS mutation cases. The gene discussed is KRAS; the disease is neoplasm.